International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions
The University of Queensland · Children's Health Queensland Hospital and Health Service · +42 more institutions
Abstract
The goal of this paper is to provide updated diagnostic criteria for the epilepsy syndromes that have a variable age of onset, based on expert consensus of the International League Against Epilepsy Nosology and Definitions Taskforce (2017-2021). We use language consistent with current accepted epilepsy and seizure classifications and incorporate knowledge from advances in genetics, electroencephalography, and imaging. Our aim in delineating the epilepsy syndromes that present at a variable age is to aid diagnosis and to guide investigations for etiology and treatments for these patients.
Citation impact
- FWCI
- 33.26
- Percentile
- 100%
- References
- 125
Authors
20- KRKate RineyCorresponding
The University of Queensland, Children's Health Queensland Hospital and Health Service
- ABAlicia Bogacz
Universidad de la República de Uruguay, Universidad de Montevideo
- ESErnest Somerville
UNSW Sydney, Prince of Wales Hospital
- ÉHÉdouard Hirsch
Institut National des Sciences Appliquées de Strasbourg, National Institute of Health, Hôpital d'Hautepierre, Université de Strasbourg
- RNRima Nabbout
Hôpital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Institut des Maladies Génétiques Imagine
Topics & keywords
- Nosology
- Epilepsy
- Epilepsy syndromes
- Etiology
- Psychology
- Psychiatry
- Electroencephalography
- Pediatrics
Funding
- UDU.S. Department of DefenseAwards: W81XWH, W81XWH-18, W81XWH-18-1-0612
- ELEli Lilly and Company
- PPfizer
- GGlaxoSmithKline
- SSanofi
- BBiogen
- UOUniversity of Calgary
- SSunovion
- ZZogenix
- LLivaNova
- GPGW Pharmaceuticals
- ZPZynerba Pharmaceuticals
- MPMarinus Pharmaceuticals
- SLSK Life Science
- ECEuropean Commission
- ASAustrian Science Fund
- EEisai
- OPOtsuka Pharmaceutical
- BFBundesministerium für Wissenschaft und Forschung
- ENEVER Neuro Pharma
- AIAlberta Innovates
- GPG.L. Pharma
- HLH. Lundbeck A/S
- EEpilepsiatutkimussäätiö
- NNeuraxpharm
- ATArvelle Therapeutics
- NINational Institutes of HealthAwards: U54 NS100064, NS100064, W81XWH, NS43209
- AAllergan
- CSCumming School of Medicine, University of Calgary
- GBGreenwich Biosciences
- CICanadian Institutes of Health Research
- NINational Institute of Neurological Disorders and StrokeAwards: U54 NS100064, NS43209, NS100064
- UPUCB Pharma